Search

Your search keyword '"Harmand, Pierre-Olivier"' showing total 15 results
Start Over Author "Harmand, Pierre-Olivier"
15 results on '"Harmand, Pierre-Olivier"'

2. A new hybrid record linkage process to make epidemiological databases interoperable: application to the GEMO and GENEPSO studies involving BRCA1 and BRCA2 mutation carriers

Author

Jiao, Yue, Lesueur, Fabienne, Azencott, Chloé-Agathe, Laurent, Maïté, Mebirouk, Noura, Laborde, Lilian, Beauvallet, Juana, Dondon, Marie-Gabrielle, Eon-Marchais, Séverine, Laugé, Anthony, Noguès, Catherine, Andrieu, Nadine, Stoppa-Lyonnet, Dominique, Caputo, Sandrine, Boutry-Kryza, Nadia, Calender, Alain, Giraud, Sophie, Léone, Mélanie, Bressac- de Paillerets, Brigitte, Caron, Olivier, Guillaud-Bataille, Marine, Bignon, Yves-Jean, Uhrhammer, Nancy, Bonadona, Valérie, Lasset, Christine, Berthet, Pascaline, Castera, Laurent, Vaur, Dominique, Bourdon, Violaine, Noguchi, Tetsuro, Popovici, Cornel, Remenieras, Audrey, Sobol, Hagay, Coupier, Isabelle, Harmand, Pierre-Olivier, Pujol, Pascal, Vilquin, Paul, Dumont, Aurélie, Révillion, Françoise, Muller, Danièle, Barouk-Simonet, Emmanuelle, Bonnet, Françoise, Bubien, Virginie, Longy, Michel, Sevenet, Nicolas, Gladieff, Laurence, Guimbaud, Rosine, Feillel, Viviane, Toulas, Christine, Dreyfus, Hélène, Leroux, Dominique, Peysselon, Magalie, Rebischung, Christine, Baurand, Amandine, Bertolone, Geoffrey, Coron, Fanny, Faivre, Laurence, Goussot, Vincent, Jacquot, Caroline, Sawka, Caroline, Kientz, Caroline, Lebrun, Marine, Prieur, Fabienne, Fert-Ferrer, Sandra, Mari, Véronique, Venat-Bouvet, Laurence, Bézieau, Stéphane, Delnatte, Capucine, Mortemousque, Isabelle, Coulet, Florence, Soubrier, Florent, Warcoin, Mathilde, Bronner, Myriam, Lizard, Sarab, Sokolowska, Johanna, Collonge-Rame, Marie-Agnès, Damette, Alexandre, Gesta, Paul, Lallaoui, Hakima, Chiesa, Jean, Molina-Gomes, Denise, Ingster, Olivier, Manouvrier-Hanu, Sylvie, Lejeune, Sophie, Pontois, Pauline, Lyonnet, Dominique Stoppa, Gauthier-Villars, Marion, Buecher, Bruno, Mouret-Fourme, Emmanuelle, Fricker, Jean-Pierre, Luporsi, Elisabeth, Frenay, Marc, Eisinger, Francois, Moretta, Jessica, Dugast, Catherine, Colas, Chrystelle, Lortholary, Alain, Vennin, Philippe, Adenis, Claude, Nguyen, Tan Dat, Rossi, Annick, Tinat, Julie, Tennevet, Isabelle, Limacher, Jean-Marc, Maugard, Christine, Bignon, Jean-Yves, Demange, Liliane, Cohen-Haguenauer, Odile, Gilbert, Brigitte, Zattara-Cannoni, Hélène, Institut Curie [Paris], Université Paris sciences et lettres (PSL), Cancer et génome: Bioinformatique, biostatistiques et épidémiologie d'un système complexe, MINES ParisTech - École nationale supérieure des mines de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Bioinformatique (CBIO), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Unité de génétique et biologie des cancers (U830), Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris Descartes - Paris 5 (UPD5), Aix Marseille Université (AMU), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Paris (UP), Nadia Boutry-Kryza, Alain Calender, Sophie Giraud, Mélanie Léone, Brigitte Bressac-de-Paillerets, Olivier Caron, Marine Guillaud-Bataille, Yves-Jean Bignon, Nancy Uhrhammer, Valérie Bonadona, Christine Lasset, Pascaline Berthet, Laurent Castera, Dominique Vaur, Violaine Bourdon, Catherine Noguès, Tetsuro Noguchi, Cornel Popovici, Audrey Remenieras, Hagay Sobol, Isabelle Coupier, Pierre-Olivier Harmand, Pascal Pujol, Paul Vilquin, Aurélie Dumont, Françoise Révillion, Danièle Muller, Emmanuelle Barouk-Simonet, Françoise Bonnet, Virginie Bubien, Michel Longy, Nicolas Sévenet, Laurence Gladieff, Rosine Guimbaud, Viviane Feillel, Christine Toulas, Hélène Dreyfus, Dominique Leroux, Magalie Peysselon, Christine Rebischung, Amandine Baurand, Geoffrey Bertolone, Fanny Coron, Laurence Faivre, Vincent Goussot, Caroline Jacquot, Caroline Sawka, Caroline Kientz, Marine Lebrun, Fabienne Prieur, Sandra Fert-Ferrer, Véronique Mari, Laurence Vénat-Bouvet, Stéphane Bézieau, Capucine Delnatte, Isabelle Mortemousque, Florence Coulet, Florent Soubrier, Mathilde Warcoin, Myriam Bronner, Sarab Lizard, Johanna Sokolowska, Marie-Agnès Collonge-Rame, Alexandre Damette, Paul Gesta, Hakima Lallaoui, Jean Chiesa, Denise Molina-Gomes, Olivier Ingster, Sylvie Manouvrier-Hanu, Sophie Lejeune, Catherine Noguès, Lilian Laborde, Pauline Pontois, Dominique Stoppa-Lyonnet, Marion Gauthier-Villars, Bruno Buecher, Olivier Caron, Emmanuelle Mouret-Fourme, Jean-Pierre Fricker, Christine Lasset, Valérie Bonadona, Pascaline Berthet, Laurence Faivre, Elisabeth Luporsi, Marc Frénay, Laurence Gladieff, Paul Gesta, Hagay Sobol, François Eisinger, Jessica Moretta, Michel Longy, Catherine Dugast, Chrystelle Colas, Florent Soubrier, Isabelle Coupier, Pascal Pujol, Alain Lortholary, Philippe Vennin, Claude Adenis, Tan Dat Nguyen, Capucine Delnatte, Annick Rossi, Julie Tinat, Isabelle Tennevet, Jean-Marc Limacher, Christine Maugard, Yves-Jean Bignon, Liliane Demange, Hélène Dreyfus, Odile Cohen-Haguenauer, Brigitte Gilbert, Dominique Leroux, Hélène Zattara-Cannoni, Mines Paris - PSL (École nationale supérieure des mines de Paris), Université Paris Cité (UPCité), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Génétique et évolution des maladies infectieuses (GEMI), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD [France-Sud]), Malbec, Odile, and Maladies infectieuses et vecteurs : écologie, génétique, évolution et contrôle (MIVEGEC)

Subjects
Risk, Medicine (General), Databases, Factual, Epidemiology, Computer science, [SDV]Life Sciences [q-bio], Breast Neoplasms, Health Informatics, computer.software_genre, Cohort Studies, 03 medical and health sciences, Record linkage, R5-920, 0302 clinical medicine, Humans, Genetic Predisposition to Disease, Prospective Studies, 030212 general & internal medicine, AdaBoost, Supervised machine learning, BRCA2 Protein, Linkage (software), [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, Database, BRCA1 Protein, Random forest, Support vector machine, Identifier, [SDV] Life Sciences [q-bio], Identification (information), Probabilistic linkage, Hybrid process, 030220 oncology & carcinogenesis, Mutation, Mutation (genetic algorithm), Female, computer, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Research Article
Abstract

Background Linking independent sources of data describing the same individuals enable innovative epidemiological and health studies but require a robust record linkage approach. We describe a hybrid record linkage process to link databases from two independent ongoing French national studies, GEMO (Genetic Modifiers of BRCA1 and BRCA2), which focuses on the identification of genetic factors modifying cancer risk of BRCA1 and BRCA2 mutation carriers, and GENEPSO (prospective cohort of BRCAx mutation carriers), which focuses on environmental and lifestyle risk factors. Methods To identify as many as possible of the individuals participating in the two studies but not registered by a shared identifier, we combined probabilistic record linkage (PRL) and supervised machine learning (ML). This approach (named “PRL + ML”) combined together the candidate matches identified by both approaches. We built the ML model using the gold standard on a first version of the two databases as a training dataset. This gold standard was obtained from PRL-derived matches verified by an exhaustive manual review. Results The Random Forest (RF) algorithm showed a highest recall (0.985) among six widely used ML algorithms: RF, Bagged trees, AdaBoost, Support Vector Machine, Neural Network. Therefore, RF was selected to build the ML model since our goal was to identify the maximum number of true matches. Our combined linkage PRL + ML showed a higher recall (range 0.988–0.992) than either PRL (range 0.916–0.991) or ML (0.981) alone. It identified 1995 individuals participating in both GEMO (6375 participants) and GENEPSO (4925 participants). Conclusions Our hybrid linkage process represents an efficient tool for linking GEMO and GENEPSO. It may be generalizable to other epidemiological studies involving other databases and registries.

Published
2021
Full Text
View/download PDF

4. Combining Homologous Recombination and Phosphopeptide-binding Data to Predict the Impact of BRCA1 BRCT Variants on Cancer Risk

Author

Petitalot, Ambre, Dardillac, Elodie, Jacquet, Eric, Nhiri, Naima, Guirouilh-Barbat, Josee, Julien, Patrick, Bouazzaoui, Isslam, Bonte, Dorine, Feunteun, Jean, Schnell, Jeff A., Lafitte, Philippe, Aude, Jean-Christophe, Nogues, Catherine, Rouleau, Etienne, Lidereau, Rosette, Lopez, Bernard S., Zinn-Justin, Sophie, Caputo, Sandrine M., Bonnet, Francoise, Jones, Natalie, Bubien, Virginie, Longy, Michel, Sevenet, Nicolas, Krieger, Sophie, Casters, Laurent, Vaur, Dominique, Uhrhammer, Nancy, Bignon, Yves Jean, Lizard, Sarab, Dumont, Aurelie, Revillion, Francoise, Leone, Melanie, Boutry-Kryza, Nadia, Sinilnikova, Olga, Remenieras, Audrey, Bourdon, Violaine, Noguchi, Tetsuro, Sobol, Hagay, Harmand, Pierre-Olivier, Vilquin, Paul, Pujol, Pascal, Jonveaux, Philippe, Bronner, Myriam, Sokolowska, Joanna, Delnatte, Capucine, Guibert, Virginie, Garrec, Celine, Bezieau, Stephan, Soubrier, Florent, Guillerm, Erell, Coulet, Florence, Lefol, Cedrick, Caux-Moncoutier, Virginie, Golmard, Lisa, Houdayer, Claude, Stoppa-Lyonnet, Dominique, Delvincoun, Chantal, Beaudoux, Olivia, Muller, Daniele, Toulas, Christine, Guillaud-Bataille, Marine, Bressac-De Paillerets, Brigitte, Unité de génétique et biologie des cancers (U830), Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Descartes - Paris 5 (UPD5), Stabilité Génétique et Oncogenèse (UMR 8200), Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Centre National de la Recherche Scientifique (CNRS), Université Paris-Sud - Paris 11 (UP11), Ligue Nationale Contre le Cancer - Paris, Ligue Nationnale Contre le Cancer, Institut de Chimie des Substances Naturelles (ICSN), Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC), Institut de Biologie Intégrative de la Cellule (I2BC), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), BioInformatique Moléculaire (BIM), Département Biologie des Génomes (DBG), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)-Institut de Biologie Intégrative de la Cellule (I2BC), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), Enveloppe Nucléaire, Télomères et Réparation de l’ADN (INTGEN), Département Biochimie, Biophysique et Biologie Structurale (B3S), Université Paris Descartes - Paris 5 (UPD5)-Institut Curie-Institut National de la Santé et de la Recherche Médicale (INSERM), Institute of Cellular and Molecular Radiobiology, Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Centre National de la Recherche Scientifique (CNRS), Hématopoïèse normale et pathologique, Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Gustave Roussy (IGR)-Université Paris-Sud - Paris 11 (UP11), Laboratoire de Biologie Intégrative (LBI), Institut Curie, CRLCC René Huguenin, Université Paris-Sud - Paris 11 (UP11)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS)-Université Paris-Saclay, Université Paris-Sud - Paris 11 (UP11)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS)-Université Paris-Saclay-Université Paris-Sud - Paris 11 (UP11)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS)-Université Paris-Saclay-Institut de Biologie Intégrative de la Cellule (I2BC), Université Paris-Sud - Paris 11 (UP11)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS)-Université Paris-Saclay-Université Paris-Sud - Paris 11 (UP11)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS)-Université Paris-Saclay, DIEP/DSV (DIEP/DSV), Université Paris Descartes - Paris 5 (UPD5)-Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Curie [Paris], Université Paris-Sud - Paris 11 (UP11)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), Université Paris-Sud - Paris 11 (UP11)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)-Université Paris-Sud - Paris 11 (UP11)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)-Institut de Biologie Intégrative de la Cellule (I2BC), Université Paris-Sud - Paris 11 (UP11)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)-Université Paris-Sud - Paris 11 (UP11)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), Ligue Nationale Contre le Cancer (LNCC), Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), and ANR-16-CE12-0011,2R-POL,ADN polymérase theta : lien entre réplication et réparation de l'ADN(2016)

Subjects
0301 basic medicine, Cancer Research, DNA repair, functional-analysis, [SDV]Life Sciences [q-bio], domain, Computational biology, Biology, medicine.disease_cause, 03 medical and health sciences, 0302 clinical medicine, medicine, ovarian, Molecular Biology, Cellular localization, Mutation, dna-damage, Phosphopeptide, Cancer, hereditary breast, structural basis, medicine.disease, 3. Good health, 030104 developmental biology, BRCT domain, Oncology, classification, 030220 oncology & carcinogenesis, repair, missense variants, Cancer research, Homologous recombination, Carcinogenesis, bach1 phosphopeptide
Abstract

BRCA1 mutations have been identified that increase the risk of developing hereditary breast and ovarian cancers. Genetic screening is now offered to patients with a family history of cancer, to adapt their treatment and the management of their relatives. However, a large number of BRCA1 variants of uncertain significance (VUS) are detected. To better understand the significance of these variants, a high-throughput structural and functional analysis was performed on a large set of BRCA1 VUS. Information on both cellular localization and homology-directed DNA repair (HR) capacity was obtained for 78 BRCT missense variants in the UMD-BRCA1 database and measurement of the structural stability and phosphopeptide-binding capacities was performed for 42 mutated BRCT domains. This extensive and systematic analysis revealed that most characterized causal variants affect BRCT-domain solubility in bacteria and all impair BRCA1 HR activity in cells. Furthermore, binding to a set of 5 different phosphopeptides was tested: all causal variants showed phosphopeptide-binding defects and no neutral variant showed such defects. A classification is presented on the basis of mutated BRCT domain solubility, phosphopeptide-binding properties, and VUS HR capacity. These data suggest that HR-defective variants, which present, in addition, BRCT domains either insoluble in bacteria or defective for phosphopeptide binding, lead to an increased cancer risk. Furthermore, the data suggest that variants with a WT HR activity and whose BRCT domains bind with a WT affinity to the 5 phosphopeptides are neutral. The case of variants with WT HR activity and defective phosphopeptide binding should be further characterized, as this last functional defect might be sufficient per se to lead to tumorigenesis. Implications: The analysis of the current study on BRCA1 structural and functional defects on cancer risk and classification presented may improve clinical interpretation and therapeutic selection.

Published
2019
Full Text
View/download PDF

6. E2F1 controls RIP140 expression

Author

Docquier, Aurélie, Augereau, Patrick, Lapierre, Marion, Harmand, Pierre-Olivier, Badia, Eric, Annicotte, Jean-Sébastien, Fajas, Lluis, Cavaillès, Vincent, Institut de recherche en cancérologie de Montpellier (IRCM - U896 Inserm - UM1), Université Montpellier 1 (UM1)-CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), This work was supported by the 'Institut National de la Santé et de la Recherche Médicale', the 9 University of Montpellier 1, the 'Association pour la Recherche sur le Cancer' [grant numbers 3494, 10 3169], the 'Institut National du Cancer' [grant number 610-3D1616], the 'Association Le cancer du 11 sein, parlons-en !' [Pink Ribbon Prize 2009], the 'Ligue Nationale contre le Cancer' [grant to P.O.H.], and 12 and the Ministère de la Recherche et de l'Enseignement Supérieur [grant number 26059-2007 to A.D.].

Subjects
endocrine system, Metabolism, breast cancer, DP1, [SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology, [SDV.CAN]Life Sciences [q-bio]/Cancer, biological phenomena, cell phenomena, and immunity, [SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism, adipocyte differentiation, Sp1
Abstract

International audience; RIP140 is a transcriptional coregulator involved in energy homeostasis and ovulation which is controlled at the transcriptional level by several nuclear receptors. We demonstrate here that RIP140 is a novel target gene of the E2F1 transcription factor. Bioinformatics analysis, gel shift assay, and chromatin immunoprecipitation demonstrate that the RIP140 promoter contains bona fide E2F response elements. In transiently transfected MCF-7 breast cancer cells, the RIP140 promoter is transactivated by overexpression of E2F1/DP1. Interestingly, RIP140 mRNA is finely regulated during cell cycle progression (5-fold increase at the G1/S and G2/M transitions). The positive regulation by E2F1 requires sequences located in the proximal region of the promoter (-73/+167), involves Sp1 transcription factors, and undergoes a negative feedback control by RIP140. Finally, we show that E2F1 participates in the induction of RIP140 expression during adipocyte differentiation. Altogether, this work identifies the RIP140 gene as a new transcriptional target of E2F1 which may explain some of the effect of E2F1 in both cancer and metabolic diseases.

Published
2012
Full Text
View/download PDF

7. Facial cutaneo-mucosal venous malformations can develop independently of mutation of TEK gene but may be associated with excessive expression of Src and p-Src.

Author

Brahami, Nabila, Subramaniam, Selvakumar, Al-Ddafari, Moudjahed Saleh, Elkaim, Cecile, Harmand, Pierre-Olivier, Sari, Badr-Eddine, Lefranc, Gérard, and Aribi, Mourad

Subjects
GENETIC mutation, IMMUNOBLOTTING, NUCLEOTIDE sequencing, GERM cells, PROTEIN-tyrosine kinases
Abstract

We aimed to search for mutations in the germline and somatic DNA of the TEK gene and to analyze the expression level of Src and phospho-Src (p-Src) in tumor and healthy tissues from patients with facial cutaneo-mucosal venous malformations (VMCM). Eligible patients from twelve families and thirty healthy controls were recruited respectively at the Departments of Stomatology and Oral Surgery, and Transfusion Medicine of Tlemcen University Medical Centre. Immunoblot analyses of Src and p-Src were performed after direct DNA sequencing. No somatic or germline mutations were found in all the 23 exons and their 5' and 3' intronic flanking regions, except for one case in which a c.3025+20- 3025+22 del mutation was highlighted at the intron 15, both in the germline and somatic DNA. Additionally, elevated expression levels of Src and p-Src were observed only in the patient with such mutation. However, when normalized to β-actin, the overall relative expression levels of both Src and p-Src were significantly increased in VMCM tissues when compared to healthy tissues (for both comparisons, p <0.001). In conclusion, we confirm the outcomes of our previous work suggesting that VMCM can develop independently of mutation of the TEK gene. Additionally, the results for Src activity are of particular interest in the context of specific targeted therapies and biological diagnosis. Nevertheless, such a conclusion should be confirmed through a mechanistic study and/or in a satisfactory number of patients. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

8. The RIP140 Gene Is a Transcriptional Target of E2F1

Author

Docquier, Aurélie, primary, Augereau, Patrick, additional, Lapierre, Marion, additional, Harmand, Pierre-Olivier, additional, Badia, Eric, additional, Annicotte, Jean-Sébastien, additional, Fajas, Lluis, additional, and Cavaillès, Vincent, additional

Published
2012
Full Text
View/download PDF

11. Specific Activity of Class II Histone Deacetylases in Human Breast Cancer Cells

Author

Duong, Vanessa, primary, Bret, Caroline, additional, Altucci, Lucia, additional, Mai, Antonello, additional, Duraffourd, Céline, additional, Loubersac, Julie, additional, Harmand, Pierre-Olivier, additional, Bonnet, Sandrine, additional, Valente, Sergio, additional, Maudelonde, Thierry, additional, Cavailles, Vincent, additional, and Boulle, Nathalie, additional

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results